Clinical trial
A Phase Ib /II Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)
NCT04260217 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib /II Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)
- Lead sponsor
- Ascentage Pharma Group Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 30, 2021
- Completion date
- August 13, 2025
- Enrollment
- 46 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.